Emraclidine's failure in phase 2 trials is a significant setback for AbbVie's neuroscience pipeline. This was a very ...

AbbVie faces setback as schizophrenia trial for emraclidine fails, but still has potential with other assets from Cerevel.

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

On Monday, AbbVie Inc (NYSE:ABBV) stock plunged after two trials investigating emraclidine as a once-daily, oral monotherapy ...

Negative data cost AbbVie billions of dollars in market value and convinced analysts Bristol Myers had placed a better bet in ...

Biopharmaceutical company AbbVie, Inc. (ABBV) announced Monday that its two Phase 2 EMPOWER trials investigating emraclidine as a ...

JPMorgan notes that AbbVie (ABBV) announced that its two Phase 2 EMPOWER trials evaluating emraclidine in schizophrenia did not meet their ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

Emraclidine was expected to be a competitor to Bristol Myers Squibb’s recently approved Cobenfy, but trial results put its ...

The FDA added a warning to the label of esketamine nasal spray (Spravato), noting that long-term cognitive and memory ...

AbbVie stock drops after Phase 2 trials of emraclidine fail to meet primary endpoint. The company continues data analysis for ...